Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test

Table 3 Concordance between tuberculin skin test (TST), QuantiFERON-TB Gold (QFG) and T-SPOT.TB in all the patients, in patients with past or current tuberculosis (TB) or previous treatment for latent TB infection (LTBI), and patients with no past or current TB nor treatment for LTBI

	All patients	Patients with past or current TB or treatment for LTBI	Patients with no past or current TB nor treatment for LTBI
QFG vs TST	0.548	0.524	0.437
	(0.417-0.621)	(0.359-0.615)	(0.233-0.663)
T.SPOT.TB (Mc)* vs TST*	0.397	0.415	0.238
	(0.268-0.515)	(0.233-0.663)	(0.092-0.392)
T.SPOT.TB (FDAc)** vs TST*	0.483	0.493	0.359
	(0.339-0.609)	(0.249-0.685)	(0.176-0.541)
T.SPOT.TB (FDAc)*** vs TST*	0.392	0.482	0.237
	(0.269-0.500)	(0.243-0.665)	(0.100-0.372)
T.SPOT.TB (FDAc)**** vs TST*	0.455	0.430	0.350
	(0.315-0.583)	(0.186-0.622)	(0.171-0.533)
T.SPOT.TB (Mc)* vs QFG*	0.365	0.331	0.324
	(0.255-0.437)	(0.110-0.483)	(0.196-0.381)
T.SPOT.TB (FDAc)** vs QFG*	0.478	0.456	0.426
	(0.348-0.554)	(0.213-0.601)	(0.259-0.504)
T.SPOT.TB (FDAc)*** vs QFG*	0.351	0.355	0.289
	(0.250-0.411)	(0.143-0.477)	(0.171-0.341)
T.SPOT.TB (FDAc)**** vs QFG*	0.464	0.447	0.414
	(0.336-0.560)	(0.208-0.611)	(0.245-0.515)

NOTE. Data are kappa (κ) coefficient and lower and upper limits of the 95% confidence interval.
Mc: Manufacturer’s interpretation criteria; FDAc: Food and Drug Agency’s interpretation criteria.
*Excluding indeterminate results; ** excluding invalid and borderline results; *** excluding invalid results and borderline results considered as positive; **** excluding invalid results and borderline results considered as negative.

ISSN: 1471-2334